Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Net Cash Flow (2023 - 2025)

Monte Rosa Therapeutics (GLUE) has 3 years of Net Cash Flow data on record, last reported at $138.9 million in Q3 2025.

  • For Q3 2025, Net Cash Flow rose 728.35% year-over-year to $138.9 million; the TTM value through Sep 2025 reached $82.8 million, up 23.77%, while the annual FY2024 figure was $96.4 million, 33.03% up from the prior year.
  • Net Cash Flow reached $138.9 million in Q3 2025 per GLUE's latest filing, up from -$9.0 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $138.9 million in Q3 2025 and bottomed at -$145.7 million in Q1 2025.
  • Average Net Cash Flow over 3 years is $13.9 million, with a median of $9.1 million recorded in 2024.
  • Peak YoY movement for Net Cash Flow: tumbled 816.59% in 2024, then soared 728.35% in 2025.
  • A 3-year view of Net Cash Flow shows it stood at $69.1 million in 2023, then skyrocketed by 42.73% to $98.6 million in 2024, then soared by 40.84% to $138.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Net Cash Flow were $138.9 million in Q3 2025, -$9.0 million in Q2 2025, and -$145.7 million in Q1 2025.